MYC-mediated synthetic lethality for treating tumors

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Deregulated c-MYC (MYC) is a key driver in numerous human cancers, making it a critical therapeutic target.
• Current MYC-targeting therapies have shown limited success, necessitating novel treatment strategies.
• MYC protein stability and activity are tightly regulated by complex cellular mechanisms, including the GSK3/FBW7 axis.

Purpose of the Study:

• To explore the therapeutic potential of small molecule inhibitors (SMIs) in targeting MYC for cancer treatment.
• To investigate the concept of MYC-mediated synthetic lethality (MYC-SL) as a treatment strategy.
• To elucidate the mechanisms by which SMIs modulate MYC levels and induce tumor cell death.

Main Methods:

• Review of existing literature on MYC regulation and small molecule inhibitor development.
• Analysis of strategies involving upregulation or downregulation of MYC expression via SMIs.
• Examination of the role of the GSK3/FBW7 axis and other signaling pathways in MYC modulation.

Main Results:

• SMIs can induce MYC-SL by either increasing MYC levels (inactivating GSK3β/FBW7 and CK1) leading to apoptosis, or decreasing MYC levels (activating GSK3β/FBW7) leading to tumor regression.
• The GSK3/FBW7 axis is a central regulator of MYC protein turnover and a key target for SMI-based therapies.
• Several SMIs targeting MYC are progressing through clinical trials.

Conclusions:

• Small molecule inhibitors represent a promising therapeutic avenue for MYC-overexpressing cancers.
• Targeting MYC stability and activity through SMIs offers a viable strategy for inducing synthetic lethality.
• Future cancer treatments may involve combination therapies utilizing SMIs for cancers with MYC and MYC-SL gene co-overexpression.